We took part in engaging discussions spanning methodological challenges, replicability of cost-effectiveness models, debates around orphan drug designation, and the impact of MFN on European HTA and pricing.
It was especially great to reconnect with health economists across academia, industry and the public sector, and to have so many thoughtful conversations around our posters.
Vi ses igen nรคsta รฅr!
